London, 18 October 2016
For immediate release
Smiths Group establishes a Euro Medium Term Note Programme
Smiths Group plc ("the Company") announces today that it has established a €2.5 billion Euro Medium Term Note Programme ("the EMTN programme") with its ten relationship banks as dealers.
The EMTN programme will facilitate the issuance by the Company of senior notes over time in various currencies and maturities as a continuing element of its financing strategy. Notes issued under the EMTN programme will be guaranteed by Smiths Group International Holdings Limited and will rank pari passu with all of the Company's outstanding senior notes and other debt obligations.
Chris O'Shea, Chief Financial Officer, said:
"This programme underpins Smiths Group's existing strategy to finance our balance sheet from the rated public debt markets. It provides us with increased flexibility in refinancing our debt maturities over the next two years, and in financing portfolio management activities, such as the agreement we announced in April to acquire Morpho Detection."
A base prospectus dated 17 October 2016 relating to the establishment of the EMTN programme ("the Prospectus") has been approved by the UK Listing Authority and is available for viewing.
To view the Prospectus, please paste the following URL into the address bar of your browser: http://www.rns-pdf.londonstockexchange.com/rns/7487M_-2016-10-17.pdf
The Prospectus has been submitted to the National Storage Mechanism and will shortly be available for inspection at: www.Hemscott.com/nsm.do.
Andrew Lappin, Smiths Group
+44 (0)20 7004 1657
+44 (0)78 5461 1966
Kirsty Law, Smiths Group
+44 (0)20 7004 1672
+44 (0)75 8315 4386
Andrew Lorenz, FTI Consulting
+44 (0)203 727 1323
+44 (0)777 564 1807
Smiths is a global technology company listed on the London Stock Exchange (SMIN) and operates a sponsored level one ADR programme (SMGZY). A world leader in the practical application of technologies, Smiths Group delivers products and services for the threat & contraband detection, medical devices, energy and communications markets worldwide. Our products and services make the world safer, healthier and more productive. Smiths Group employs 22,000 people in over 50 countries. For more information visit www.smiths.com
Disclaimer - intended addressees
Please note that the information contained in the Prospectus may be addressed to and/or targeted at persons who are residents of particular countries (specified in the Prospectus) only and is not intended for use and should not be relied upon by any person outside these countries and/or to whom the offer contained in the Prospectus is not addressed. Prior to relying on the information contained in the Prospectus, you must ascertain from the Prospectus whether or not you are one of the intended addressees of the information contained therein.
In particular, the Prospectus does not constitute an offer of securities for sale in the United States. Neither the Prospectus nor this announcement is intended for distribution in the United States. The securities described herein have not been, and will not be, registered under the U.S. Securities Act of 1933, as amended (the "Securities Act"), or under any relevant securities laws of any state of the United States of America and are subject to U.S. tax law requirements. Subject to certain exceptions, the securities may not be offered or sold within the United States or to, or for the account or benefit of, U.S. persons or to persons within the United States of America, as such terms are defined in Regulation S under the Securities Act. There will be no public offering of the securities in the United States.
Your right to access this service is conditional upon complying with the above requirement.
This information is provided by RNS